Custirsen Sodium (Prostate Cancer) - Forecast and Market Analysis to 2022 - New Study Released


Fast Market Research recommends "Custirsen Sodium (Prostate Cancer) - Forecast and Market Analysis to 2022" from GlobalData, now available


Published on 28 March 2013


by Bill Thompson

(WireNews+Co)

Boston, MA

GlobalData has released its new PharmaPoint Drug Evaluation report, "Custirsen Sodium (Prostate Cancer) - Forecast and Market Analysis to 2022". The recent approvals of second-line metastatic castration-resistant prostate cancer (mCRPC) therapies like J&J's Zytiga (abiraterone acetate) and Medivation/Astellas' Xtandi (enzalutamide) will drive strong market growth over the next decade. These safe and orally administered treatments will provide safety and convenience benefits over the current standard of care, chemotherapy with docetaxel, while prolonging the overall survival of patients with mCRPC. The December 12, 2012 FDA approval of Zytiga for the added indication of chemotherapy-naive mCRPC marks the onset of a new treatment paradigm for the disease, in which chemotherapy is relegated to second-line therapy and beyond. For patients with earlier-stage prostate cancer, androgen deprivation therapy with LHRH agonists and first-generation antiandrogens remains the standard of care for suppressing testosterone levels and temporarily controlling the disease.

View Full Report Details and Table of Contents (http://www.fastmr.com/prod/544198_custirsen_sodium_prostate_cancer_forecast_and.aspx?afid=201)

Custirsen (OGX-011) is an FIC drug in development for the first-line treatment of mCRPC in combination with docetaxel and prednisone. It is an mRNA antisense inhibitor of clusterin production that is administered intravenously on a weekly basis. Clusterin is a chaperone protein expressed at high levels in prostate cancer cells, and levels of the drug increase further after castration therapy and in castration-resistant tissues. Custirsen was discovered and initially developed by OncoGenex Pharmaceuticals and Isis Pharmaceuticals, and was licensed to Teva in 2009. The drug has been fast-tracked by the FDA, and the companies are currently sponsoring the Phase III Synergy trial under an FDA Special Protocol Assessment (SPA)

Scope

- Overview of Prostate cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Custirsen including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Custirsen for the top nine countries from 2012 to 2022.
- Sales information covered for the US, Japan, UK, France, Germany, Spain, Italy , Canada, and Australia

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Prostate cancer
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Custirsen performance
- Obtain sales forecast for Custirsen from 2012-2022 in nine markets (US, Japan, UK, France, Germany, Spain, Italy , Canada, and Australia)




Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget.  For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.


Contacts

  •  
  • Bill Thompson
  • Fast Market Research, Inc.
  • PR Contact
  • Tel: +14134857001
  •  
Enter your email:
Enter Subject:
Enter your message:
Please enter this numbers in the fields:
 
  Click image to get a new code.
Enter code:
 

Posted 2013-03-28 08:35:00